Header

UZH-Logo

Maintenance Infos

Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know


Schreiner, Philipp; Mueller, Nicolas J; Fehr, Jan; Maillard, Michel H; Brand, Stephan; Michetti, Pierre; Schoepfer, Alain; Restellini, Sophie; Vulliemoz, Marianne; Vavricka, Stephan R; Juillerat, Pascal; Rogler, Gerhard; Biedermann, Luc (2021). Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. Journal of Crohn's & Colitis, 15(2):316-325.

Abstract

Primary Varicella Zoster virus (VZV) infection results in varicella (chickenpox) while its reactivation results in herpes zoster (HZ; shingles). Patients with Inflammatory Bowel Disease (IBD) are susceptible to complications of primary VZV infection and have an increased risk of HZ. Concerns of VZV and HZ infection in the IBD population has been highlighted by the emergence of JAK-inhibitors and their safety profile in this patient population such as tofacitinib for the treatment of ulcerative colitis (UC). The current pipeline of emerging therapies include novel molecules targeting multiple pathways including JAK/signal transducer and cytokine signalling pathways such as JAK/STAT. Hence VZV and HZ will be increasingly relevant for gastroenterologists treating IBD patients in light of these emerging therapies.

Abstract

Primary Varicella Zoster virus (VZV) infection results in varicella (chickenpox) while its reactivation results in herpes zoster (HZ; shingles). Patients with Inflammatory Bowel Disease (IBD) are susceptible to complications of primary VZV infection and have an increased risk of HZ. Concerns of VZV and HZ infection in the IBD population has been highlighted by the emergence of JAK-inhibitors and their safety profile in this patient population such as tofacitinib for the treatment of ulcerative colitis (UC). The current pipeline of emerging therapies include novel molecules targeting multiple pathways including JAK/signal transducer and cytokine signalling pathways such as JAK/STAT. Hence VZV and HZ will be increasingly relevant for gastroenterologists treating IBD patients in light of these emerging therapies.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gastroenterology and Hepatology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 February 2021
Deposited On:29 Oct 2020 17:38
Last Modified:02 Feb 2021 02:03
Publisher:Oxford University Press
ISSN:1873-9946
OA Status:Closed
Publisher DOI:https://doi.org/10.1093/ecco-jcc/jjaa132
PubMed ID:32592587

Download

Full text not available from this repository.
View at publisher

Get full-text in a library